Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNYSE:CYBNNASDAQ:IMTXNYSEAMERICAN:PFNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.54-3.3%$7.43$5.90▼$34.11$550.35M2.21.44 million shs2.93 million shsCYBNCybin$8.15-5.0%$7.52$4.81▼$13.88$187.65M0.68268,517 shs182,543 shsIMTXImmatics$5.43-2.9%$5.23$3.30▼$13.09$660.02M0.83673,511 shs563,289 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+1.34%+4.29%+7.41%-71.68%CYBNCybin0.00%+4.76%+2.39%+28.55%+2,108.67%IMTXImmatics0.00%-3.21%-2.51%+20.40%-53.27%PFNXPfenex0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.4199 of 5 stars4.32.00.00.01.52.51.3CYBNCybin2.6601 of 5 stars3.60.00.00.02.50.81.3IMTXImmatics2.8583 of 5 stars3.64.00.00.02.81.70.0PFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29169.09% UpsideCYBNCybin 3.25Buy$86.00955.21% UpsideIMTXImmatics 3.20Buy$14.67170.10% UpsidePFNXPfenex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYBN, IMTX, ARVN, and PFNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.09N/AN/A$8.17 per share0.92CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AIMTXImmatics$168.65M3.91$0.24 per share22.22$5.12 per share1.06PFNXPfenexN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)CYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/AIMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)PFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ALatest CYBN, IMTX, ARVN, and PFNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58CYBNCybinN/A24.2424.24IMTXImmaticsN/A10.2810.28PFNXPfenexN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CYBNCybin17.94%IMTXImmatics64.41%PFNXPfenexN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas4.73%CYBNCybin15.00%IMTXImmaticsN/APFNXPfenexN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableCYBNCybin5023.02 million17.96 millionNot OptionableIMTXImmatics260121.55 millionN/AOptionablePFNXPfenex7134.30 millionN/ANot OptionableCYBN, IMTX, ARVN, and PFNX HeadlinesRecent News About These CompaniesUCB posts more supportive data from Humira rival bimekizumabNovember 6, 2024 | pharmaphorum.comPNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLast available seats at PFS West Coast Conference next weekMay 19, 2023 | pharmaphorum.comPLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksMay 4, 2023 | news.google.comN150+ Active Companies working to develop 160+ Pipeline ... - Digital JournalApril 12, 2023 | news.google.comNHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqApril 6, 2023 | news.google.comNLENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalMarch 29, 2023 | news.google.comNRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalMarch 17, 2023 | news.google.comNGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireMarch 15, 2023 | news.google.comNSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneMarch 15, 2023 | news.google.comNOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalMarch 13, 2023 | news.google.comNCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRMarch 1, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianFebruary 23, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireFebruary 22, 2023 | news.google.comNBiosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalFebruary 7, 2023 | news.google.comNInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comJanuary 27, 2023 | news.google.comNOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalJanuary 27, 2023 | news.google.comNInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRJanuary 6, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, IMTX, ARVN, and PFNX Company DescriptionsArvinas NASDAQ:ARVN$7.54 -0.26 (-3.33%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$14.50 +6.96 (+92.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cybin NYSE:CYBN$8.15 -0.43 (-5.01%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$8.27 +0.12 (+1.47%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Immatics NASDAQ:IMTX$5.43 -0.16 (-2.86%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$5.65 +0.22 (+4.05%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
